TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33829783

Group type: EXPERIMENTAL
Intervention: AG-270, a first-in-class oral MAT2A inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33829867

Group type: EXPERIMENTAL
Intervention: Higher total screen exposure
Number of subjects: 250
Study: 33829988

Group type: EXPERIMENTAL
Intervention: Noergaard technique
Number of subjects: 151
Study: 33829991

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping
Number of subjects: 140
Study: 33830058

Group type: EXPERIMENTAL
Intervention: iCST app intervention in addition to usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: treatment-as-usual
Number of subjects: 60
Study: 33830168

Group type: EXPERIMENTAL
Intervention: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard chemoradiation therapy (not explicitly detailed in the abstract).
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy.
Number of subjects: 27
Study: 33830342

Group type: EXPERIMENTAL
Intervention: Nivolumab with prior cetuximab
Number of subjects: 256

Group type: COMPARATOR
Intervention: Nivolumab without prior cetuximab
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Nivolumab with neck dissection
Number of subjects: 256

Group type: COMPARATOR
Intervention: Nivolumab without neck dissection
Number of subjects: 256
Study: 33830377

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 2520
Study: 33830399

Group type: EXPERIMENTAL
Intervention: QFR measured before PCI
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: QFR measured after PCI
Number of subjects: 111
Study: 33830407

Group type: EXPERIMENTAL
Intervention: ASP4132 5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 10 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 7.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 10 mg intermittent dosing (3 days on, 4 days off)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 15 mg intermittent dosing (1 day on, 6 days off)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 overall
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASP4132 pharmacokinetics
Number of subjects: 39
Study: 33830871

Group type: EXPERIMENTAL
Intervention: Salivary VZV DNA detection using real-time PCR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Abdominopelvic computed tomography (APCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: COVID-19 patients
Number of subjects: 50
Study: 33831045

Group type: EXPERIMENTAL
Intervention: Low-dose beetroot juice (BJ) supplementation (nitrate: 1.3 mmol/L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose beetroot juice (BJ) supplementation (nitrate: 4.3 mmol/L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BJ) supplementation (nitrate: 0.9 mmol/L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (BJ) supplementation
Number of subjects: 60
Study: 33831519

Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug-coated balloon (DCB)
Number of subjects: 418
Study: 33831732

Group type: EXPERIMENTAL
Intervention: Cemiplimab 200 mg every 2 weeks intravenously for up to 48 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 20
Study: 33831812

Group type: EXPERIMENTAL
Intervention: Weight-based teasing (WBT)
Number of subjects: 201
Study: 33831901

Group type: EXPERIMENTAL
Intervention: Automated administration of ephedrine or phenylephrine via the ADIVA algorithm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ADIVA system with noninvasive continuous haemodynamic monitoring
Number of subjects: 45
Study: 33832305

Group type: EXPERIMENTAL
Intervention: Nomogram risk threshold of 28% for low Global Health Status (GHS)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: BMI <23, age >65 years, female sex
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nomogram score ≥72
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: C-statistics of the final predictive model
Number of subjects: 173
Study: 33832543

Group type: EXPERIMENTAL
Intervention: Virtual family-based treatment (vFBT)
Number of subjects: 0
Study: 33832565

Group type: EXPERIMENTAL
Intervention: Saliva specimen
Number of subjects: 19110

Group type: EXPERIMENTAL
Intervention: Oropharyngeal swab (OPS)
Number of subjects: 19110

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab (NPS)
Number of subjects: 19110
Study: 33832610

Group type: EXPERIMENTAL
Intervention: SAVOR-TIMI 53 trial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33832946

Group type: EXPERIMENTAL
Intervention: N-803 plus rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous N-803 plus rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CITE-seq analysis
Number of subjects: 0
Study: 33833048

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Selection based on KIR genotypes
Number of subjects: 69
Study: 33834845

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5116

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5116
Study: 33834847

Group type: EXPERIMENTAL
Intervention: Robotic-assisted stent implantation
Number of subjects: 10
Study: 33835229

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg once daily plus letrozole 2.5 mg once daily
Number of subjects: 26
Study: 33835265

Group type: EXPERIMENTAL
Intervention: SARS-CoV‑2 IgG and IgM antibody tests using a high sensitivity/low specificity threshold
Number of subjects: 235

Group type: COMPARATOR
Intervention: Positive controls with proven COVID-19
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Serum samples from healthcare workers
Number of subjects: 235
Study: 33835383

Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 459
Study: 33835628

Group type: EXPERIMENTAL
Intervention: Floatation-Reduced Environmental Stimulation Therapy (REST) for 90 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (resting supine in a zero-gravity chair) for 90 minutes
Number of subjects: 0
Study: 33835823

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryoballoon catheter ablation
Number of subjects: 0
Study: 33835826

Group type: EXPERIMENTAL
Intervention: IRONMAN registry strategies for site selection, recruitment, engagement, and retention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens.
Number of subjects: 0
Study: 33835830

Group type: EXPERIMENTAL
Intervention: Yoga-based breathing techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33835866

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or patient/physician decision
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1004
Study: 33835936

Group type: EXPERIMENTAL
Intervention: Email-based dialectical behavioral therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person dialectical behavioral therapy (DBT)
Number of subjects: 0
Study: 33835977

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33836153

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-positive MPM
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-negative MPM
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Serious treatment-related adverse events
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Grade 3-4 treatment-related events
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Common grade 3-4 treatment-related events
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Treatment-related death
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Discontinuation of pembrolizumab
Number of subjects: 118
Study: 33836187

Group type: EXPERIMENTAL
Intervention: AAP model using 3 criteria (both parents born outside the EU, low weight at 1 year, weaning to cow's milk without supplemental iron)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Newly derived simple prediction tool (≥1 criterion among the 3 previous plus duration of iron-rich formula consumption <12 months)
Number of subjects: 568
Study: 33836262

Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No EVOO treatment
Number of subjects: 84
Study: 33836671

Group type: EXPERIMENTAL
Intervention: Radiotherapy for high-grade gliomas
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Seizure diary
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Weekly neurologist consultations
Number of subjects: 35
Study: 33836889

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) covered by state Medicaid programs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Legislative policies mandating coverage of routine medical costs for patients in clinical trials
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acceptance of out-of-state Medicaid insurance
Number of subjects: 10

Group type: COMPARATOR
Intervention: Coverage for travel and lodging for the patient and one caregiver
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medicaid fee-for-service plans
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insurance authorization process for alloHCT
Number of subjects: 10

Group type: COMPARATOR
Intervention: Legislative policy for access to clinical trials and out-of-state benefits
Number of subjects: 10
Study: 33836987

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 33
Study: 33837055

Group type: EXPERIMENTAL
Intervention: Belapectin (2, 4, or 8 mg/kg IV 60 min before pembrolizumab) + pembrolizumab (200 mg IV every 3 weeks for five cycles)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Belapectin + pembrolizumab
Number of subjects: 20
Study: 33837786

Group type: EXPERIMENTAL
Intervention: Multilevel intervention combining MOST and CBPR principles, cost under $250 per person.
Number of subjects: 0
Study: 33837912

Group type: EXPERIMENTAL
Intervention: Centralized hospitalization in the COVID-19 unit of the Paracelsus Medical University Salzburg, irrespective of symptoms.
Number of subjects: 0
Study: 33838339

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 478
Study: 33838463

Group type: EXPERIMENTAL
Intervention: EHF audiometry at 9, 10, 11.2, 12.5, 14 and 16 kHz
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EHF audiometry at 14 kHz
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EHF audiometry at 16 kHz
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EHF audiometry comparing age groups 6-9 years and 10-14 years at 16 kHz
Number of subjects: 126

Group type: COMPARATOR
Intervention: EHF audiometry comparing right and left ears
Number of subjects: 126

Group type: COMPARATOR
Intervention: EHF audiometry comparing genders
Number of subjects: 126
Study: 33838625

Group type: EXPERIMENTAL
Intervention: G207 (oncolytic herpes simplex virus type 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: G207
Number of subjects: 12
Study: 33839064

Group type: EXPERIMENTAL
Intervention: Anti-Tat immunity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches aiming at reinforcing anti-Tat immunity
Number of subjects: 0
Study: 33839074

Group type: EXPERIMENTAL
Intervention: ET-directed therapy (monotherapy)
Number of subjects: 1207
Study: 33839487

Group type: EXPERIMENTAL
Intervention: Depression Sensitivity Index (DSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical and cognitive concerns (DSPCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social concerns (DSSC)
Number of subjects: 0
Study: 33839905

Group type: EXPERIMENTAL
Intervention: Whole food-based low-calorie diet combined with app-based digital education and behavioral change program
Number of subjects: 24
Study: 33840050

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 30
Study: 33840068

Group type: EXPERIMENTAL
Intervention: 3-month community intervention consisting of group education for type 2 diabetes knowledge, diet, exercise in combination with usual diabetes care
Number of subjects: 364

Group type: COMPARATOR
Intervention: Usual diabetes care alone (control)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 3-month community intervention
Number of subjects: 364
Study: 33840295

Group type: EXPERIMENTAL
Intervention: Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Before Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: After Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120
Study: 33840396

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 91
Study: 33840477

Group type: EXPERIMENTAL
Intervention: IVC reconstruction
Number of subjects: 17
Study: 33840726

Group type: EXPERIMENTAL
Intervention: Steatohepatitis
Number of subjects: 420

Group type: COMPARATOR
Intervention: No FLD
Number of subjects: 420
Study: 33840725

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatments
Number of subjects: 22492

Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy
Number of subjects: 22492

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 22492

Group type: EXPERIMENTAL
Intervention: Treatment compliance
Number of subjects: 22492

Group type: EXPERIMENTAL
Intervention: Longer treatment durations
Number of subjects: 22492
Study: 33840743

Group type: EXPERIMENTAL
Intervention: High Total Cholesterol (TC)
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: High Low-Density Lipoprotein Cholesterol (LDL-C)
Number of subjects: 2312
Study: 33840749

Group type: EXPERIMENTAL
Intervention: Quantitatively prescribed PD-AFO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Original AFO
Number of subjects: 10
Study: 33840791

Group type: EXPERIMENTAL
Intervention: Retinal vascular occlusion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Choroidopathy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Retinal vasculitis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall visual acuity
Number of subjects: 23
Study: 33841012

Group type: EXPERIMENTAL
Intervention: Korea Red Ginseng (KRG) 2,000 mg/day for 30 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 33841184

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study: 33842385

Group type: EXPERIMENTAL
Intervention: Different sequencing approaches targeting different 16S rRNA variable regions
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Different DNA processing and sequencing approaches
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Re-processing and re-sequencing of microbiome
Number of subjects: 412
Study: 33842418

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33842519

Group type: EXPERIMENTAL
Intervention: Psychobiotic Supplementation of PS128
Number of subjects: 0
Study: 33842870

Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg/mL, 1 mL, five injections)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 33842889

Group type: EXPERIMENTAL
Intervention: Preprocessing of radiomics features using PyRadiomics
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Normalization and intensity quantization
Number of subjects: 48
Study: 33842908

Group type: EXPERIMENTAL
Intervention: UNI91104 (inhaled and intranasal niclosamide)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 33843247

Group type: EXPERIMENTAL
Intervention: hs-CRP (high-sensitivity C-reactive protein)
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Inflammation score
Number of subjects: 3784
Study: 33843258

Group type: EXPERIMENTAL
Intervention: Consensus decision-making on continuation and regimen of preoperative antiplatelet therapy (APT)
Number of subjects: 3582

Group type: COMPARATOR
Intervention: Arbitrary APT not based on a consensus decision
Number of subjects: 3582

Group type: COMPARATOR
Intervention: Arbitrary APT
Number of subjects: 3582
Study: 33843594

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support with Patient Education (CDS-E)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support without Patient Education (CDS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard Practice
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study: 33843599

Group type: EXPERIMENTAL
Intervention: Web-based dialectical behavior therapy (DBT) skills site with secure message coaching; no specific dosage or duration mentioned.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DBT skills website users
Number of subjects: 60
Study: 33843785

Group type: EXPERIMENTAL
Intervention: IBS-D
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IBS-C
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 33843815

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation with myeloablative conditioning (thiotepa, busulfan, and cyclophosphamide) without radiation, followed by 12 post-transplant lumbar punctures with intrathecal cytarabine.
Number of subjects: 2
Study: 33843946

Group type: EXPERIMENTAL
Intervention: Time-limited trials (TLTs) as the default care-planning approach
Number of subjects: 209
Study: 33844007

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 33844036

Group type: EXPERIMENTAL
Intervention: Study period (March-April 2020)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Control period (2018-2019)
Number of subjects: 532
Study: 33844429

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study: 33844595

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg or 200 mg every 3 weeks)
Number of subjects: 28
Study: 33844623

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (three doses: Day 1, Month 2, Month 6)
Number of subjects: 201
Study: 33844938

Group type: EXPERIMENTAL
Intervention: Social Media Support from Friends
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33844998

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33845032

Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin system inhibitors (RASi)
Number of subjects: 6503

Group type: COMPARATOR
Intervention: No RASi
Number of subjects: 6503
Study: 33845259

Group type: EXPERIMENTAL
Intervention: Post-transplantation bendamustine (PTB) at doses of 140 mg/m², 100 mg/m², and 70 mg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0
Study: 33845648

Group type: EXPERIMENTAL
Intervention: Modified Chinese Autism Spectrum Rating Scale
Number of subjects: 2013
Study: 33845785

Group type: EXPERIMENTAL
Intervention: Risk assessment framework for trial activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on protective measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of risk based on staff proximity, exposure time, and potential viral aerosolization
Number of subjects: 0
Study: 33845865

Group type: EXPERIMENTAL
Intervention: Externally stented SVG
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-stented SVG
Number of subjects: 102
Study: 33845893

Group type: EXPERIMENTAL
Intervention: Short-term (ST) metformin withdrawal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Long-term (LT) metformin withdrawal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (ST and LT)
Number of subjects: 44
Study: 33845905

Group type: EXPERIMENTAL
Intervention: Dalpiciclib 100 mg, 125 mg, and 150 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dalpiciclib 125 mg and 150 mg cohorts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dalpiciclib 150 mg cohort
Number of subjects: 40
Study: 33846069

Group type: EXPERIMENTAL
Intervention: Grey-scale ultrasonography
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FibroTest™ score
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ActiTest™ score
Number of subjects: 28
Study: 33846084

Group type: EXPERIMENTAL
Intervention: cSAA assay measuring serum anticholinergic activity
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: cSAA assay
Number of subjects: 311
Study: 33846112

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (TBx)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined biopsy (TBx plus SBx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic biopsy (SBx)
Number of subjects: 0
Study: 33846719

Group type: EXPERIMENTAL
Intervention: Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Malaria treatment after diagnosis alongside IPTp-SP
Number of subjects: 1850
Study: 33846844

Group type: EXPERIMENTAL
Intervention: 300 MBq of a novel theranostic PET radiopharmaceutical
Number of subjects: 9
Study: 33846843

Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal MRI (no suspicious enhancement)
Number of subjects: 102